Literature DB >> 31582565

Myosin motor domains carrying mutations implicated in early or late onset hypertrophic cardiomyopathy have similar properties.

Carlos D Vera1, Chloe A Johnson2, Jonathan Walklate2, Arjun Adhikari3, Marina Svicevic4, Srboljub M Mijailovich5, Ariana C Combs1, Stephen J Langer1, Kathleen M Ruppel3, James A Spudich3, Michael A Geeves6, Leslie A Leinwand7.   

Abstract

Hypertrophic cardiomyopathy (HCM) is a common genetic disorder characterized by left ventricular hypertrophy and cardiac hyper-contractility. Mutations in the β-cardiac myosin heavy chain gene (β-MyHC) are a major cause of HCM, but the specific mechanistic changes to myosin function that lead to this disease remain incompletely understood. Predicting the severity of any β-MyHC mutation is hindered by a lack of detailed examinations at the molecular level. Moreover, because HCM can take ≥20 years to develop, the severity of the mutations must be somewhat subtle. We hypothesized that mutations that result in early onset disease would have more severe changes in function than do later onset mutations. Here, we performed steady-state and transient kinetic analyses of myosins carrying one of seven missense mutations in the motor domain. Of these seven, four were previously identified in early onset cardiomyopathy screens. We used the parameters derived from these analyses to model the ATP-driven cross-bridge cycle. Contrary to our hypothesis, the results indicated no clear differences between early and late onset HCM mutations. Despite the lack of distinction between early and late onset HCM, the predicted occupancy of the force-holding actin·myosin·ADP complex at [Actin] = 3 K app along with the closely related duty ratio (the fraction of myosin in strongly attached force-holding states), and the measured ATPases all changed in parallel (in both sign and degree of change) compared with wildtype (WT) values. Six of the seven HCM mutations were clearly distinct from a set of previously characterized DCM mutations.
© 2019 Vera et al.

Entities:  

Keywords:  actin-myosin; cardiomyopathy; hypertrophic cardiomyopathy; kinetics; mathematical modeling; molecular motor; structure-function

Mesh:

Substances:

Year:  2019        PMID: 31582565      PMCID: PMC6873187          DOI: 10.1074/jbc.RA119.010563

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  59 in total

1.  Design of protein function leaps by directed domain interface evolution.

Authors:  Jin Huang; Akiko Koide; Koki Makabe; Shohei Koide
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-29       Impact factor: 11.205

2.  Gene-specific modifying effects of pro-LVH polymorphisms involving the renin-angiotensin-aldosterone system among 389 unrelated patients with hypertrophic cardiomyopathy.

Authors:  Meghan J Perkins; Sara L Van Driest; Erik G Ellsworth; Melissa L Will; Bernard J Gersh; Steve R Ommen; Michael J Ackerman
Journal:  Eur Heart J       Date:  2005-08-08       Impact factor: 29.983

3.  Phosphorylation and calcium antagonistically tune myosin-binding protein C's structure and function.

Authors:  Michael J Previs; Ji Young Mun; Arthur J Michalek; Samantha Beck Previs; James Gulick; Jeffrey Robbins; David M Warshaw; Roger Craig
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-23       Impact factor: 11.205

4.  Purification of actin from cardiac muscle.

Authors:  H G Zot; J D Potter
Journal:  Prep Biochem       Date:  1981

Review 5.  Inherited cardiomyopathies: molecular genetics and clinical genetic testing in the postgenomic era.

Authors:  Polakit Teekakirikul; Melissa A Kelly; Heidi L Rehm; Neal K Lakdawala; Birgit H Funke
Journal:  J Mol Diagn       Date:  2012-12-27       Impact factor: 5.568

6.  The R249Q hypertrophic cardiomyopathy myosin mutation decreases contractility in Drosophila by impeding force production.

Authors:  Kaylyn M Bell; William A Kronert; Alice Huang; Sanford I Bernstein; Douglas M Swank
Journal:  J Physiol       Date:  2019-04-04       Impact factor: 5.182

Review 7.  Disease pathways and novel therapeutic targets in hypertrophic cardiomyopathy.

Authors:  Houman Ashrafian; William J McKenna; Hugh Watkins
Journal:  Circ Res       Date:  2011-06-24       Impact factor: 17.367

8.  Phenotype and prognostic correlations of the converter region mutations affecting the β myosin heavy chain.

Authors:  Diego García-Giustiniani; Michael Arad; Martín Ortíz-Genga; Roberto Barriales-Villa; Xusto Fernández; Isabel Rodríguez-García; Andrea Mazzanti; Elena Veira; Emilia Maneiro; Paula Rebolo; Iván Lesende; Laura Cazón; Dov Freimark; Juan Ramón Gimeno-Blanes; Christine Seidman; Jonathan Seidman; William McKenna; Lorenzo Monserrat
Journal:  Heart       Date:  2015-05-02       Impact factor: 5.994

9.  Contractility parameters of human β-cardiac myosin with the hypertrophic cardiomyopathy mutation R403Q show loss of motor function.

Authors:  Suman Nag; Ruth F Sommese; Zoltan Ujfalusi; Ariana Combs; Stephen Langer; Shirley Sutton; Leslie A Leinwand; Michael A Geeves; Kathleen M Ruppel; James A Spudich
Journal:  Sci Adv       Date:  2015-10-09       Impact factor: 14.136

Review 10.  The Molecular Mechanisms of Mutations in Actin and Myosin that Cause Inherited Myopathy.

Authors:  Steven Marston
Journal:  Int J Mol Sci       Date:  2018-07-11       Impact factor: 5.923

View more
  7 in total

Review 1.  Multiscale simulations of left ventricular growth and remodeling.

Authors:  Hossein Sharifi; Charles K Mann; Alexus L Rockward; Mohammad Mehri; Joy Mojumder; Lik-Chuan Lee; Kenneth S Campbell; Jonathan F Wenk
Journal:  Biophys Rev       Date:  2021-08-25

2.  Cardiomyopathy mutations impact the actin-activated power stroke of human cardiac myosin.

Authors:  Wanjian Tang; Jinghua Ge; William C Unrath; Rohini Desetty; Christopher M Yengo
Journal:  Biophys J       Date:  2021-04-20       Impact factor: 3.699

3.  Myosin with hypertrophic cardiac mutation R712L has a decreased working stroke which is rescued by omecamtiv mecarbil.

Authors:  Aaron Snoberger; Bipasha Barua; Jennifer L Atherton; Henry Shuman; Eva Forgacs; Yale E Goldman; Donald A Winkelmann; E Michael Ostap
Journal:  Elife       Date:  2021-02-19       Impact factor: 8.140

Review 4.  Critical Evaluation of Current Hypotheses for the Pathogenesis of Hypertrophic Cardiomyopathy.

Authors:  Marko Ušaj; Luisa Moretto; Alf Månsson
Journal:  Int J Mol Sci       Date:  2022-02-16       Impact factor: 5.923

Review 5.  Hypertrophic cardiomyopathy: Mutations to mechanisms to therapies.

Authors:  Masataka Kawana; James A Spudich; Kathleen M Ruppel
Journal:  Front Physiol       Date:  2022-09-26       Impact factor: 4.755

6.  A role for actin flexibility in thin filament-mediated contractile regulation and myopathy.

Authors:  Meera C Viswanathan; William Schmidt; Peter Franz; Michael J Rynkiewicz; Christopher S Newhard; Aditi Madan; William Lehman; Douglas M Swank; Matthias Preller; Anthony Cammarato
Journal:  Nat Commun       Date:  2020-05-15       Impact factor: 14.919

7.  Hypertrophic cardiomyopathy β-cardiac myosin mutation (P710R) leads to hypercontractility by disrupting super relaxed state.

Authors:  Alison Schroer Vander Roest; Chao Liu; Makenna M Morck; Kristina Bezold Kooiker; Gwanghyun Jung; Dan Song; Aminah Dawood; Arnav Jhingran; Gaspard Pardon; Sara Ranjbarvaziri; Giovanni Fajardo; Mingming Zhao; Kenneth S Campbell; Beth L Pruitt; James A Spudich; Kathleen M Ruppel; Daniel Bernstein
Journal:  Proc Natl Acad Sci U S A       Date:  2021-06-15       Impact factor: 11.205

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.